Home Newsfeeds Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.25) per share. This is a 525 percent decrease over losses of $(0.04) per share from the same period last year.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.25) per share. This is a 525 percent decrease over losses of $(0.04) per share from the same period last year.

Morgan Stanley Maintains Equal-Weight on Unum, Raises Price Target to $50

By Benzinga Newsdesk

February 23, 9:39 AM

Morgan Stanley analyst Nigel Dally maintains Unum (NYSE:UNM) with a Equal-Weight and raises the price target from $48 to $50.

UNM

Fed President Mary Daly Says Fed Has More Work To Do When It Comes To Rate Hikes; Fed Policy Is In Modestly Restrictive Territory; Latest Inflation Data Moving In Right Direction

By Benzinga Newsdesk

November 21, 2:03 PM

- Reuters

SPY

PepsiCo Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

By Avi Kapoor

February 9, 2:19 AM

PepsiCo, Inc. (NASDAQ: PEP) is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 9, 2024.

PEP

NanoVibronix Announces Presentation Of Independent Testing Results Of UroShield At ICS Annual Meeting

By Happy Mohamed

September 6, 8:40 AM

Dr. Sandra Wilks to Present Findings from University of Southampton Study in Toronto NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®

NAOV

Cocrystal Pharma Q2 EPS $(0.25) Down From $(0.04) YoY

Related Posts

Morgan Stanley Maintains Equal-Weight on Unum, Raises Price Target to $50

Fed President Mary Daly Says Fed Has More Work To Do When It Comes To Rate Hikes; Fed Policy Is In Modestly Restrictive Territory; Latest Inflation Data Moving In Right Direction

PepsiCo Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

NanoVibronix Announces Presentation Of Independent Testing Results Of UroShield At ICS Annual Meeting